Premium
Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
Author(s) -
McCulloch Rory,
Visco Carlo,
Eyre Toby A.,
Frewin Rebecca,
Phillips Neil,
Tucker David L.,
Quaglia Francesca M.,
McMillan Annabel,
Lambert Jonathan,
Crosbie Nicola,
Rule Simon
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16416
Subject(s) - mantle cell lymphoma , medicine , bendamustine , rituximab , cytarabine , bruton's tyrosine kinase , gastroenterology , refractory (planetary science) , surgery , oncology , lymphoma , chemotherapy , tyrosine kinase , physics , receptor , astrobiology
Summary Patients with mantle cell lymphoma progressing on Bruton’s tyrosine kinase inhibitor (BTKi) have very poor prognosis and there is currently no standard of care. In this retrospective cohort study, patients progressing on BTKi received R‐BAC (rituximab, bendamustine, cytarabine). Overall response rate was 83% (complete response 60%) and 31% were bridged to allogeneic stem cell transplant (alloSCT). Median progression‐free survival was 10.1 months (95% confidence interval (CI) 6·9–13·3) and median overall survival was 12·5 months (95% CI 11·0–14·0). In those consolidated with alloSCT only one patient relapsed. R‐BAC demonstrates a high response rate in the post‐BTKi setting and in transplant eligible patients is an effective bridge to alloSCT.